Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Endoplasmic reticulum protein 27 (ERP27) is a non-catalytic member of the protein disulfide isomerase (PDI) family, localized in the endoplasmic reticulum. Structurally, it consists of two thioredoxin-like domains homologous to the non-catalytic b and b′ domains of PDI, but it lacks the active site for redox catalysis and is therefore not involved in thiol-disulfide oxidoreduction[1][3][5]. ERP27 contains an N-terminal signal sequence, two TRX-like domains, and a C-terminal ER-retention sequence[5]. It binds unfolded proteins via a hydrophobic pocket in its C-terminal domain and may function as a molecular chaperone by binding substrate proteins and possibly recruiting other PDI-like proteins such as PDIA3 (ERp57)[5][3][4]. ERP27 is believed to participate in the unfolded protein response, but its specific biological function remains largely uncharacterized[1][5][3]. There is currently no evidence supporting a therapeutic role, disease-specific targeting, or clinical use of ERP27 as a drug target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Endoplasmic reticulum protein 27 (ERP27).